ATHERSYS, INC / NEW Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-09: Form 8-K; Period of report 2016-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-09-28: Form 8-K; Period of report 2016-09-28; Description 8.01 Other Events; Details 8.01.
- 2016-09-12: Form 8-K; Period of report 2016-09-12; Description 8.01 Other Events; Details 8.01.
- 2016-08-09: Form 8-K; Period of report 2016-08-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-09 | 8-K | 2016-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2016, Athersys, Inc. issued a press release announcing financial results for its third quarter ended September 30, 2016. | d289783d8k.htm |
| 2016-09-28 | 8-K | 2016-09-28 | 8.01 Other Events | 8.01 On September 28, 2016, Athersys, Inc. (“Athersys”) announced the agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment (SPA) for the design and planned analysis of a Phase 3 clinical trial of Athersys’ novel MultiStem® cell therapy product for the treatment of ischemic stroke. | d267526d8k.htm |
| 2016-09-12 | 8-K | 2016-09-12 | 8.01 Other Events | 8.01 On September 12, 2016, Athersys, Inc. (“Athersys”) announced the authorization the commencement by its collaborator, HEALIOS K.K., of a clinical trial in Japan evaluating the safety and efficacy of administration of MultiStem® cell therapy, Athersys’ novel stem cell therapy, to treat patients who have suffered an ischemic stroke. | d195327d8k.htm |
| 2016-08-09 | 8-K | 2016-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2016, Athersys, Inc. issued a press release announcing financial results for its second quarter ended June 30, 2016. | d208308d8k.htm |
| 2016-06-22 | 8-K | 2016-06-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 20, 2016, at the Annual Meeting of the Stockholders (the “Annual Meeting”) of Athersys, Inc. (the “Company”), the stockholders of the Company, upon the recommendation of the Company’s Board of Directors (the “Board”), approved the Athersys, Inc. Amended and Restated 2007 Long-Term Incentive Plan (the “Plan”). 5.07 Set forth below are the voting results for each of the matters submitted to a vote of the Company’s stockholders at the Annual Meeting. | d217019d8k.htm |
| 2016-05-05 | 8-K | 2016-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2016, Athersys, Inc. issued a press release announcing financial results for its first quarter ended March 31, 2016. | d188339d8k.htm |
| 2016-04-22 | 8-K | 2016-04-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 22, 2016, Mr. Kenneth H. Traub notified Athersys, Inc. (the “Company”) that he will be unable to stand for reelection as a member of the Company’s Board of Directors at the Company’s 2016 annual stockholder meeting on June 20, 2016. | d186562d8k.htm |
| 2016-03-10 | 8-K | 2016-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2016, Athersys, Inc. issued a press release announcing financial results for its fourth quarter ended December 31, 2015. | d159568d8k.htm |
| 2016-01-13 | 8-K | 2016-01-07 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 8, 2016, the Company announced a license agreement with Healios to develop and commercialize MultiStem® cell therapy for ischemic stroke and potentially other indications in Japan. | d116562d8k.htm |